To support the development and commercialization of a novel immunotherapy, biopharmaceutical company TG Therapeutics has signed a deal to license MaxCyte’s Flow Electroporation

为了支持新型免疫疗法的开发和商业化，生物制药公司TG Therapeutics签署了一项协议，授权MaxCyte的流动电穿孔

®

®

technology and ExPERT

技术和专家

™

™

platform.

平台。

Under the terms of the agreement, the company will have nonexclusive research, clinical, and commercial rights to use MaxCyte’s electroporation technology. For their part, MaxCyte will receive annual licensing fees and program-related revenue.

根据协议条款，该公司将拥有使用MaxCyte电穿孔技术的非专有研究、临床和商业权利。就他们而言，MaxCyte将获得年度许可费和项目相关收入。

TG Therapeutics is focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. Its portfolio includes azercabtagene zapreleucel (azer-cel), an allogenic CD19 CAR T cell therapy for treating autoimmune diseases and other non-oncology indications developed by Precision BioSciences.

TG Therapeutics专注于获取，开发和商业化B细胞疾病的新型治疗方法。其产品组合包括Azercabtagen zapreleucel（azer cel），一种用于治疗自身免疫性疾病和其他非肿瘤适应症的同种异体CD19 CAR T细胞疗法，由Precision BioSciences开发。

TG signed an agreement with the gene-editing company last year and acquired a worldwide license to the investigational allogeneic therapy. It has since received clearance from the FDA for an Investigational New Drug application for azer-cel in progressive forms of multiple sclerosis. The company intends to launch a Phase I trial for the treatment this year..

TG去年与该基因编辑公司签署了一项协议，并获得了该研究性异基因治疗的全球许可证。此后，它已获得FDA批准，用于azer cel进行性多发性硬化症的研究性新药申请。该公司计划在今年启动该治疗的第一阶段试验。。

Commenting on the agreement, Maher Masoud, MaxCyte’s president and CEO noted, “Our technology has been integral to the manufacturing of allogeneic T cell immunotherapies and was efficiently transferred from Precision BioSciences when TG Therapeutics obtained global rights for azer-cel.” Through the partnership with TG, MaxCyte will “continue to support the development of azer-cel to expand the application to autoimmune diseases,” he added..

MaxCyte总裁兼首席执行官Maher Masoud在评论该协议时指出，“我们的技术是制造同种异体T细胞免疫疗法不可或缺的一部分，当TG Therapeutics获得azer cel的全球权利时，我们的技术已从Precision BioSciences有效转移。”通过与TG的合作，MaxCyte将“继续支持azer cel的开发，以扩大其在自身免疫性疾病中的应用”，他补充道。。

The partnership with TG Therapeutics is one of several inked by MaxCyte in recent years. Last May, MaxCyte granted

与TG Therapeutics的合作是MaxCyte近年来签署的几项合作协议之一。去年5月，MaxCyte被授予

Legend Biotech

联想生物科技

a nonexclusive worldwide license to use its electroporation technology to develop and commercialize cell-based therapeutic products. Before that, MaxCyte signed a similar deal with

使用其电穿孔技术开发和商业化基于细胞的治疗产品的非排他性全球许可证。在此之前，MaxCyte与

Walking Fish Therapeutics

步行鱼疗法

centered on B cell-based therapeutics.

以B细胞为基础的疗法为中心。

News

新闻